The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.
Canopy offers products and services for gene editing, gene expression analysis and regulation, and bioprocessing, as well as a multi-omic immune profiling platform.
The pair are working on reagents and mass spec approaches to improve isolation and analysis of crosslinked peptides for protein interaction and structural studies.
The company reported Q2 revenues of $424.6 million, down from $490.2 million in Q2 2019 but beating the consensus Wall Street estimate of $390.9 million.
Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.
